Johnson & Johnson has submitted an sNDA to the FDA for its nasal spray SPRAVATO to treat treatment-resistant depression as a monotherapy. Positive outcomes from the Phase IV TRD4005 study showed significant improvements in depression symptoms with sustained effects for at least four weeks.